The 4th International Conference on
WT1 in Human Neoplasia
Meeting Presidents:
Haruo Sugiyama (Osaka University, Osaka)
Eckhard Thiel (Charité, Campus Benjamin Franklin, Berlin)
September 10(Thu)-11(Fri), 2009
Senri Life Science Center, Osaka, JAPAN
1-4-2 Shin-Senrihigashimachi Toyonaka-city Osaka, Japan
TEL: +81-6-6873-2010
The 4th International Conference on WT1 in Human Neoplasia
2009
Meeting presidents
Haruo Sugiyama
(Osaka University, Osaka, Japan)
Eckhard Thiel
(Charité, Campus Benjamin Franklin, Berlin, Germany)
Co-Chairs
Yoshihiro Oka
(Osaka University, Osaka, Japan)
Ulrich Keilholz
(Charité, Campus Benjamin Franklin, Berlin, Germany)
Program Committee
Elizabeth M. Algar
(University of Melbourne, Melbourne, Australia)
A. John Barrett
(National Institute of Health, Bethesda, USA)
Zwi N. Berneman
(Antwerp University, Belgium)
Martin A. Cheever
(Seattle Cancer Care Alliance, Fred Huchinson/
University of Washington Cancer Consortium, Seattle, USA )
Daniela Cilloni
(University of Turin, Turin, Italy)
Alexander Gaiger
(Medical University of Viena, Viena, Austria)
Nicholas D. Hastie
(Western General Hospital, Edinburgh, UK)
Joop H. Jansen
(University Medical Center Nijimegen, Nijimegen,
the Netherlands)
Yuji Heike
(National Cancer Center Hospital, Tokyo, Japan)
Ichiro Kawase
(Osaka University, Osaka, Japan)
Ulrich Keilholz
(Charité, Berlin, Germany)
Yusuke Oji
(Osaka University, Osaka, Japan)
Yoshihiro Oka
(Osaka University, Osaka, Japan)
Katayoun Rezvani
(Hammersmith Hospital, London, UK)
Giuseppe Saglio
(University of Turin, Turin, Italy)
Hans Stauss
(University College London, London, UK)
Mathias Theobald
(University Medical Center Utrecht, the Netherlands)
Masaki Yasukawa
(Ehime University, Toon, Japan)
1
The 4th International Conference on WT1 in Human Neoplasia
Conference Schedule
September 10 (Thu)
From
To
13:00
13:10
Opening
13:10
15:35
Session I. WT1-directed immunity in mice models and humans
Chairs: Mathias Theobald & Hans J. Stauss
15:35
16:15
16:15
17:10
Coffee Break
Session II. Clinical trials of WT1-targeting immunotherapy-part I
Chairs: Yoshihiro Oka & Katayoun Rezvani
17:10
18:35
Session III. WT1 as a disease marker and WT1 mutation-part I
Chairs: Daniela Cilloni & Giuseppe Saglio
Reception party (Senri Hankyu Hotel)
19:10
September 11 (Fri)
9:00
10:00
Session II. Clinical trials of WT1-targeting immunotherapy-part II
Chairs: A. John Barrett & Zwi N. Berneman
10:00
11:00
Session II. Clinical trials of WT1-targeting immunotherapy-part III
Chairs: Ulrich Keilholz & Masaki Yasukawa
11:00
12:10
Session IV. Physiology and pathophysiology of WT1-part I
Chairs: Joop H. Jansen & Aihong Li
12:10
14:00
Lunch Time
* Program committee
14:00
15:00
Session IV. Physiology and pathophysiology of WT1-part II
Chairs: David Loeb & Yusuke Oji
15:00
15:40
15:40
16:40
Coffee Break
Session III. WT1 as a disease marker and WT1 mutation-part II
Chairs: Yuji Heike& Elizabeth M. Algar
16:40
17:00
Closing
2
2009
The 4th International Conference on WT1 in Human Neoplasia
2009
Access Map
Senri Life
Science Center
Senri-Chuou Station
(Subway)
Shopping area
Senri Hankyu
Hotel
From Kansai International Airport (KIX)
50min by JR EXPRESS train (Haruka) to Shin-Osaka Sta.
15min by Subway Midou-suji line from Shin-Osaka to Senri-Chuou Sta.
From Itami International Airport (ITM)
12min by monorail
Around Senri-Chuou Station
Senri Lifescience Center (3min' walk)
Senri Hankyu Hotel (5min' walk)
Shopping Mall (0-5min' walk)
including restaurants, electronics shop, etc
3
The 4th International Conference on WT1 in Human Neoplasia
4
2009
The 4th International Conference on WT1 in Human Neoplasia
2009
PRESENTATION GUIDELINES
[Presentation Time]
12 min for presentation and 3 min for Q&A are given to each presentation.
[Preparation of Presentation Materials]
All speakers must use electronic files (in PowerPointTM in Win) to present at
the conference. Powerpoint 2007 is available on the prepared PC.
Please prepare your files in PowerPoint and check whether your file is
compatible to Win PC.
The name of file should include your presentation number (shown in the
conference program) and your name like “1-1_OJI”.
All the speakers must bring their presentation files in their media (USB
flash-memory or CD-ROM) to the [Speaker’s reception desk] at the time
below.
Please upload your file to the appointed folder in the prepared computer (Win).
And open your file and make sure whether it displays appropriately on the
computer monitor. Our staff will assist you.
Speakers for
Session I
Session II part 1
Session III part 1
Session II parts 2&3
Session IV part 1
Session IV part 2
Session III part 2
[operation of Speaker’s reception desk]
12:00-13:00
on Sept. 10 (1st day)
15:35-16:15
on Sept. 10 (1st day)
15:35-16:15
on Sept. 10 (1st day)
8:00-9:00
on Sept. 11 (2nd day)
8:00-9:00
on Sept. 11 (2nd day)
13:00-14:00
on Sept. 11 (2nd day)
15:00-15:40
on Sept. 11 (2nd day)
If you use your own Mac PC, please prepare connectors and adopters, which is
necessary to connect with the projector equipment.
Prepared computer cable
All the files uploaded in the prepared computer will be surely deleted after
your presentation.
5
The 4th International Conference on WT1 in Human Neoplasia
2009
Program
Session I
Session II
Session III
Session IV
*At
:
:
:
:
WT1-directed immunity in mice models and humans
Clinical trials of WT1-targeting immunotherapy
WT1 as a disease marker and WT1 mutation
Physiology and pathophysiology of WT1
the conference, taking photograph or Video is prohibited throughout
the presentation time to protect presenting unpublished data.
September 10 (Thu)
13:00 Opening
Session I: WT1-directed immunity in mice models and humans
Chairs: Mathias Theobald & Hans J. Stauss
13:10 Introductory lecture for Session I
Mathias Theobald
13:20 (1-1) WT1 IgG antibody for early detection of non-small cell lung
cancer and as its prognostic factor
Yusuke Oji1, Yayoi Kitamura2, Eriko Kamino2, Aiko Kitano2, Noriyoshi
Sawabata3, Masayoshi Inoue3, Masahide Mori4, Shin-ichi Nakatsuka5,
Michiyo Nakamura2, Naoya Tatsumi2, Riichiro Nezu6, Hajime Maeda7,
Sumiyuki Nishida8, Naoki Hosen9, Akihiro Tsuboi8, Yoshihiro Oka10,
Katsuyuki Aozasa11, Meinoshin Okumura3, Ichiro Kawase8, Shinichiro
Miyoshi12, Haruo Sugiyama2
Departments of 1Cancer Stem Cell Biology, 2Functional Diagnostic Science, 3Thoracic
Surgery, 8Cancer Immunotherapy, 9Biomedical Informatics, 10Respiratory Medicine and
Allergy, Rheumatic Disease, and
11Pathology,
6
Osaka University Graduate School of
The 4th International Conference on WT1 in Human Neoplasia
2009
Medicine, Suita, Osaka, Japan, Departments of 4Respiratory Medicine and 7Thoracic
Surgery, Toneyama National Hospital, Toyonaka, Osaka, Japan,
5Department
of
Pathology, Sumitomo Hospital, Osaka, Osaka, Japan, 6Department of Surgery, Osaka
Rosai Hospital, Sakai, Osaka, Japan,
12Department
of Cancer and Thoracic Surgery,
Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama
University, Okayama, Japan.
13:35 (1-2) WT1-TCR engineered patient T cells can eliminate autologous
leukaemia blasts in NOD/SCID mice
Shao-An Xue1, Liquan Gao1, Sharyn Thomas1, Daniel P. Hart1, John Zhao Xue1,
Roopinder Gillmore1, Ralf-Holger Voss2, Emma Morris1 & Hans J. Stauss1
1Department
of Immunology, Division of Infection & Immunity, University College
London, Royal Free Hospital, Rowland Hill Street, London NW3 2PF U.K.; 2Department
of Hematology and Oncology, Johannes Gutenberg University, 55101 Mainz,
Germany.
13:50 (1-3) Design of tumor antigenic peptide for immunization with heat
shock protein 70
Tomonori Waku, Yukari Watanabe, Hirotoshi Haida, Naoko Asada, Shigeru
Kunugi, Naoki Tanaka
Department of Biomolecular Engineering, Kyoto Institute of Technology, Kyoto, Japan
14:05 (1-4) Enhancement of tumor immunity of WT1 peptide vaccination
by interferon-β administration
Hiroko Nakajima1, Yoshihiro Oka2, Akihiro Tsuboi3, Fumihiro Fujiki1, Ichiro
Kawase2,Yusuke Oji4, Haruo Sugiyama5
Departments of 1Cancer Immunology, 2Respiratory Medicine, Allergy and Rheumatic
Disease, 3Cancer Immunotherapy, 4Cancer Stem Cell Biology, 5Functional Diagnostic
Science, Osaka University Graduate School of Medicine, Osaka, Japan
14:20 (1-5) Immunohistochemical expression of the Wilms’ tumor protein
1 (WT1) in patients with acute myeloid leukemia enrolled in a
dendritic cell-based immunotherapy trial.
Anguille Sébastien1,2, Waelput Wim3, Van Tendeloo Vigor1, Berneman Zwi1,2
1Center
for Cell Therapy & Regenerative Medicine and the Depts. of 2Hematology and
3Pathology,
Antwerp University Hospital, Antwerp, Belgium
7
The 4th International Conference on WT1 in Human Neoplasia
2009
14:35 (1-6) Multiparametric detection of T cell responses following DC
vaccination: the Antwerp experience from a phase I trial in leukemia
patients
Nathalie Cools1, Evelien L.J. Smits1, Ann Van Driessche2, Barbara Stein2, Griet
Nijs2, Zwi N. Berneman1,2, Viggo F.I. Van Tendeloo1,2
1Laboratory
of Experimental Hematology, Vaccine & Infectious Disease Institute (VIDI),
Antwerp University, B-2610 Wilrijk, Belgium;
2Center
for Cellular Therapy and
Regenerative Medicine, Antwerp University Hospital, B-2650 Edegem, Belgium
14:50 (1-7) Properties of allogeneic WT1 specific T cells generated across
an HLA A2 barrier
John Barrett1, Willem Falkenburg1, Emma Gostick2, David A. Price2, Nancy F.
Hensel1, J.Joseph Melenhorst1
1Hematology
Branch, National Heart, Lung, and Blood Institute, National Institutes of
Health, Bethesda, Maryland, USA; 2Cardiff University School of Medicine, Cardiff,
United Kingdom
15:05 (1-8) WT1- targeting immuno-gene therapy for human leukemia by
using WT1-specific T cell receptor gene transfer
Hiroshi Fujiwara1, Toshiki Ochi1, Jun An1, Kozo Nagai1, Toshiaki Shirakata1,
Sachiko Okamoto2, Junichi Mineno2, Kiyotaka Kuzushima3, Hiroshi Shiku4,
Masaki Yasukawa1
1Dept.
of Bioregulatory Medicine, Ehime University Graduate School of Medicine,
Ehime, Japan.; 2 Ctr. for Cell and Gene Therapy, Takara Bio., Inc., Shiga, Japan.; 3Aichi
Cancer Centre, Nagoya, Japan.; 4Dept. of Immuno-Gene therapy, Mie University
Graduate School of Medicine, Mie, Japan
15:20 (1-9) WT1 Peptide Vaccination: T cell repertoire with emphasis of
the Vß21-family
Ulrich Keilholz1, Alberto Fusi, Anne Letsch, Antonia Busse, Eckhard Thiel,
Sebastian Ochsenreither
1Medizinische
15:35-16:15
Klinik III, Charité, Campus Benjamin Franklin, Berlin, Germany
Coffee Break
8
The 4th International Conference on WT1 in Human Neoplasia
2009
Session II: Clinical trials of WT1-targeting immunotherapy/ part I
Chairs: Yoshihiro Oka & Katayoun Rezvani
16:15 Introductory lecture for Session II
Yoshihiro Oka
16:25 (2-1) The response to repeated vaccination with PR1 and WT1
peptides admixed in Montanide adjuvant is transient and fails to
induce sustained anti-leukemia responses in patients with myeloid
malignancies
Katy Rezvani1, Agnes Yong, Stephan Mielke, Behnam Jafarpour, Rhoda
Eniafe, Laura Musse, Carol Boss, A John Barrett
1Department
of Hematology, Imperial College London, Du Cane Road, London W12
0NN, U.K.
16:40 (2-2) Phase I/II study of WT1 peptide vaccination for childhood
malignancies
Emiko Sato1, Yoshiko Hashii1, Risa Matsumura1, Hisao Yoshida1, Shigenori
Kusuki1,Hideaki Ohta1, Akihiro Tsuboi2, Yusuke Oji3, Yoshihiro Oka4, Haruo
Sugiyama3, Keiichi Ozono1
Departments of 1Pediatrics, 2Cancer Immunotherapy, 3Functional Diagnostic Science,
4Respiratory
Medicine, Allergy, and Rheumatic Diseases, Osaka University Graduate
School of Medicine, Osaka, Japan
16:55 (2-3) WT1 immunotherapy for malignant gliomas
Naoya Hashimoto1, Akihiro Tsuboi2, Yasuyoshi Chiba1, Yoshihiro Oka3, Ayako
Murao2, Yoshiko Okita1, Manabu Kinoshita1, Naoki Kagawa1, Yusuke Oji4,
Naoki Hosen4, Sumiyuki Nishida2, Toshiki Yoshimine1 and Haruo Sugiyama5
Departments of
1Neurosurgery,
2Cancer
Allergy and Rheumatic Diseases,
Immunotherapy,
4Cancer
3Respiratory
Stem Cell Biology, and
Medicine,
5Functional
Diagnostic Science, Osaka University Graduate School of Medicine, Suita 565-0871,
Japan
9
The 4th International Conference on WT1 in Human Neoplasia
2009
Session III: WT1 as a disease marker and WT1 mutation/ part I
Chairs: Daniela Cilloni & Giuseppe Saglio
17:10 Introductory lecture for Session IV
Daniela Cilloni
17:20 (3-1) Early assessment of minimal residual disease (MRD) by
optimized real-time quantitative PCR (RQ-PCR) assay for detection
of WT1 transcripts provides an independent predictor of disease
relapse in acute myeloid leukemia: A European LeukemiaNet (ELN)
study
Daniela Cilloni1, Aline Renneville2, Fabienne Hermitte3, Robert K Hills4, Sarah
Daly5, Jelena V Jovanovic6, Enrico Gottardi1, Milena Fava1, Susanne
Schnittger7, Tamara Weiss7, Barbara Izzo8, Joseph Nomdedeu9, Adrian van der
Heijden10, Bert van der Reijden10, Vincent H.J van der Velden11, Peter Rohon12,
Hans Ommen13, Jaroslav Polák14, Joop Jansen10, Claude Preudhomme2, David
Grimwade,6 Giuseppe Saglio1
1Department
of Clinical & Biological Sciences, University of Turin, Turin, Italy;
2Department
of Hematology, Biology and Pathology Center, University of Lille Medical
School, France; Cancer Research Institute, JP Aubert Center, INSERM, U-837, Team 3,
Lille, France; 3Research & Development, Ipsogen, Marseille, France; 4Department of
Haematology, School of Medicine, Cardiff University, Cardiff, United Kingdom;
5Department
Kingdom;
of Haematology, Manchester Royal Infirmary, Manchester, United
6Department
School of Medicine,
of Medical and Molecular Genetics, King’s College London
London, United Kingdom; 7MLL, Munich Leukemia Laboratory,
Munich, Germany; 8Department of Hematology, University Federico II, Naples, Italy;
9Department
of Hematology, Hospital De St Pau, Barcelona, Spain; 10Central
Hematology Laboratory, Radboud University Nijmegen Medical Centre, ijmegen Centre
for Molecular Life Sciences, Nijmegen, The Netherlands; 11Department of Immunology,
Erasmus MC, Rotterdam, Netherlands; 12Department of Hemato-oncology, University
Hospital Olomouc, Czech Republic; 13Laboratory of Immunohematology, Department of
Hematology, Århus Sygehus, THG, Århus University Hospital, Århus, Denmark;
Diagnostics, Institute of Hematology, Prague, Czech Republic.
10
14DNA
The 4th International Conference on WT1 in Human Neoplasia
2009
17:35 (3-2) WT1 expression in peripheral blood can provide more useful
information on MRD in children with AML
Karolina Kramarzova, Ludmila Boublikova, Katerina Muzikova, Jan Stary,
Jan Trka
CLIP, Department of Paediatric Hematology and Oncology, 2nd Faculty of Medicine,
Charles’ University and University Hospital in Prague – Motol, Czech Republic
17:50 (3-3) WT1 expression in patients with childhood AML undergoing
stem cell transplantation
Karolina Kramarzova, Ludmila Boublikova, Katerina Muzikova, Jan Stary, Jan
Trka
CLIP, Department of Paediatric Hematology and Oncology, 2nd Faculty of Medicine,
Charles’ University and University Hospital in Prague – Motol, Czech Republic
18:05 (3-4) Expression of WT1 and Leukemia Associated Antigens in
Peripheral Blood of AML Patients at Diagnosis and During Follow
Up.
Jaroslav Polák, Hana Hájková, Jiří Schwarz, Jana Marková, Jacqueline
Soukupová-Maaloufová, Dana Dvořáková, Cedrik Haškovec
Department of Molecular Genetics, Institute of Hematology and Blood Transfusion,
Prague, IHOK, Faculty Hospital, Brno, Czech Republic
18:20 (3-5) Relevance of Minimal Residual Disease and Chimerism for the
Detection of Relapse after Hematopoietic Stem Cell Transplantation
Bernd Gruhn, Nadine Pfaffendorf, Astrid Voigt, Felix Zintl, James Beck
Department of Pediatrics, University of Jena, Jena, Germany
19:10 Reception party
at Senri Hankyu Hotel
11
The 4th International Conference on WT1 in Human Neoplasia
2009
September 11 (Fri)
Session II: Clinical trials of WT1-targeting immunotherapy
/ part II
Chairs: A. John Barrett & Zwi N. Berneman
9:00
(2-4) A clinical trial of WT1 peptide vaccination in pediatric patients
following allogeneic stem cell transplantation
Yoshiko Hashii1 ,Hideaki Ohta1, Hisao Yoshida1, Shigenori Kusuki1, Emiko
Sato1, Akihiro Tsuboi2, Yusuke Oji3, Yoshihiro Oka4, Haruo Sugiyama3, Keiichi
Ozono1
Departments of 1Pediatrics, 2Cancer Immunotherapy, 3Functional Diagnostic Science,
4Respiratory
Medicine, Allergy, and Rheumatic Diseases, Osaka University Graduate
School of Medicine, Osaka, Japan
9:15
(2-5) Clinical efficacy of WT1 peptide vaccination in childhood
acute lymphoblastic leukemia: A Case Report
Shigenori Kusuki1, Yoshiko Hashii1, Risa Matsumura1, Hisao Yoshida1, Emiko
Sato1, Hideaki Ohta1, Akihiro Tsuboi2, Yusuke Oji3, Yoshihiro Oka4, Haruo
Sugiyama3, Keiichi Ozono1
Departments of 1Pediatrics, 2Cancer Immunotherapy, 3Functional Diagnostic Science,
4Respiratory
Medicine, Allergy, and Rheumatic Diseases, Osaka University Graduate
School of Medicine, Osaka, Japan
9:30
(2-6) A Clinical and Immunological Phase II Trial of Wilms Tumor
Gene Product 1 (WT1) Peptide Vaccination in Patients with AML
and MDS
Ulrich Keilholz1, Anne Letsch, Antonia Busse, Eckhard Thiel
1Medizinische
9:45
Klinik III, Charité, Campus Benjamin Franklin, Berlin, Germany
(2-7) Phase I/II clinical trial of HLA-A*2402 restricted WT1
peptide-based cancer vaccine in patients with advanced colorectal
cancer
Sumiyuki Nishida1, Yoshihiro Oka2, Akihiro Tsuboi1, Satoshi Ohno1, Toshiaki
12
The 4th International Conference on WT1 in Human Neoplasia
2009
Shirakata1, Yusuke Oji1, Naoki Hosen1, Satoshi Morita3, Junichi Sakamoto4,
Ichiro Kawase2, Toshinori Ito5,Mitsugu Sekimoto5,and Haruo Sugiyama6
Depts. of 1Cancer Immunotherapy, 2Respiratory Medicine, Allergy and Rheumatic
Disease, Osaka University Graduate School of Medicine, Osaka, Japan; 3Dept. of
Biostatistics & Epidemiology, Yokohama City University Medical Center, Yokohama,
Japan; 4Dept. of Health & Community Medicine, Nagoya University Graduate School of
Medicine, Nagoya, Japan; Depts. Of 5Surgery, and 6Functional Diagnostic Science,
Osaka University Graduate School of Medicine, Osaka, Japan
Session II: Clinical trials of WT1-targeting immunotherapy
/ part III
Chairs: Ulrich Keilholz & Masaki Yasukawa
10:00 (2-8) A pilot clinical trial using a multivalent WT1 peptide vaccine in
patients with mesothelioma, non-small cell lung cancer and AML
Tao Dao, Lee M. Krug, Peter Maslak, Andy Brown, Suzanne Channel, Sara
Bekele, Tatyana Koronstvit, Victoria Zakhaleva and David A. Scheinberg
Memorial Sloan-Kettering Cancer Center, New York, NY, USA
10:15 (2-9) Long-term follow-up of WT1 peptide-based immunotherapy for
the patients with acute myeloid leukemia with minimal residual
disease
Akihiro Tsuboi1, Yoshihiro Oka2, Taiichi Kyo3, Yuuta Katayama3, Olga A.
Elisseeva7, Manabu Kawakami5, Naoki Hosen6, Sumiyuki Nishida1, Ayako
Murao2, Hiroko Nakajima6, Ichiro Kawase2, Yusuke Oji6, Hiroo Dohy3, Haruo
Sugiyama7
Depts. of
1Cancer
Immunotherapy,
2Respiratory
Medicine, Allergy and Reumatic
Diseases, 6Cancer Stem Cell Biology and 7Functional Diagnostic Sciences, Osaka
University Graduate School of Medicine, Osaka, Japan; 3Hiroshima Red Cross Hospital
& Atomic Bomb Survivors Hospital, Hiroshima, Japan; 5Nissay Hospital, Osaka, Japan
13
The 4th International Conference on WT1 in Human Neoplasia
2009
10:30 (2-10) Immunotherapy of acute myeloid leukemia with dendritic
cells electroporated with mRNA encoding the Wilms’ tumor WT1
protein
Zwi N. Berneman1,3, Ann Van de Velde1,3, Ann Van Driessche2, Sébastien
Anguille1,3, Katrien Vermeulen2, Katrien Pieters2, Viggo F. Van Tendeloo1,3
1Divisions
of Hematology and of 2Molecular Diagnostics and 3Center for Cell Therapy
and Regenerative Medicine, Antwerp University Hospital, Edegem, Belgium and
Vaccine & Infectious Disease Institute, Faculty of Medicine, University of Antwerp,
Antwerp, Belgium
10:45 (2-11) Vaccine therapy using WT-1 peptide with BCG-CWS in
malignant melanoma
Megumi Nishioka1, Atsushi Tanemura1, Sumiyuki Nishida2, Yosuke Nishino1,
Eriko Iimuro1, Akiko Nakano2, Mamori Tani1, Yoshihiro Oka3, Haruo Sugiyama4,
Ichiro Katayama1
Deps of 1Dermatology, 2Cancer Immunotherapy, 3Respiratory Medicine, Allergy and
Rheumatic Diseases and 4Functional Diagnostic Science, Osaka University Graduate
School of Medicine, Osaka, Japan
Session IV: Physiology and pathophysiology of WT1/ part I
Chairs: Joop H. Jansen & Aihong Li
11:00 Introductory lecture for Session IV
Joop H. Jansen
11:10 (4-1) Wilms' tumor gene 1 (WT1) expression in subpopulations of
normal and malignant hematopoietic cells
Boublikova L1, Kramarzova K1, Mejstrikova E1, Kalina T1, Sikora J2, Stary J1,
Trka J1
1Department
of Pediatric Hematology and Oncology, 2nd Faculty of Medicine, Charles
University and University Hospital in Prague-Motol, Czech Republic; 2Institute of
Inherited Metabolic Disorders, 1st Faculty of Medicine, Charles University in Prague,
Czech Republic
14
The 4th International Conference on WT1 in Human Neoplasia
2009
11:25 (4-2) Expression of four major WT1 splicing variants in AML and
CML: development of real-time PCRs and preliminary results in
patient samples
Tereza Lopotova1, Jana Moravcova1, Vaclava Polivkova1, Jaroslav Polak1, Jiri
Schwarz2, Hana Klamova2 and Katerina Machova-Polakova1
1Department
of Molecular Genetics, Institute of Hematology and Blood Transfusion, U
Nemocnice 1, 12820, Prague, Czech Republic;
2Clinical
Department, Institute of
Hematology and Blood Transfusion, U Nemocnice 1, 12820, Prague, Czech Republic
11:40 (4-3) Acute multiple organ failure in adults deleted for the
developmental regulated Wilms tumour protein (WT1)
You-Ying Chau1, David Brownstein2, Kay Samuel3, Heidi Mjoseng 1, Elisabeth
Freyer1, Martin Waterfall4, Wen-Chin Lee5, Peter Hoenstein1, Rob Van't Hof6,
and Nicholas Hastie1
1MRC
Human Genetics Unit, Department of Medical & Developmental Genetics,
Western General Hospital, Crewe Road, Edinburgh, EH4 2XU, UK.; 2Queen's Medical
Research Institute, 47 Little France Crescent, Edinburgh EH16 4TJ, UK.; 3Scottish
National Blood Transfusion Service, Adult Cell Therapy Group, Centre for
Regenerative Medicine, Chancellors Building, New Royal Infirmary Edinburgh, 49 Little
France Cresent, Edinburgh, EH16 4SB, UK.; 4Flow Cytometry Facility, Ashworth
Laboratories, Institute of Immunology & Infection Research, School of Biological
Sciences, Kings' Buildings, Edinburgh, EH9 3JT, UK.; 5Department of Nephrology,
Chang Gung Memorial Hospital, Kaohsiung 123, Dapi Rd, Niaosong Shiang,
Kaohsiung County 833, Taiwan.;
6Rheumatic
Diseases Unit, Molecular Medicine
Centre, Institute of Genetics and Molecular Medicine, University of Edinburgh,
Edinburgh, EH4 2XU, UK.
11:55 (4-4) The role of the fusion protein, EWS/WT1, in promoting the
development of tumour
Pratiti Bandopadhayay1,2,3, Elizabeth Algar1,2,3, Anissa Jabbour1,2,3, David
Ashley1,2,3, and Paul Ekert1,2,3
1Murdoch
Children’s Research Institute, Victoria, Australia; 2Department of Paediatrics,
University of Melbourne, Australia;
3Children’s
Cancer Centre, Royal Children’s
Hospital, Victoria, Australia
12:10-14:00
Lunch Break
*Program committee
15
The 4th International Conference on WT1 in Human Neoplasia
2009
Session IV: Physiology and pathophysiology of WT1/ part II
Chairs: David Loeb & Yusuke Oji
14:00 (4-5) Wilms’ tumour 1 (WT1) gene can suppress hTERT gene
expression and telomerase activity in clear cell renal cell
carcinoma
Raviprakash T. Sitaram1, Börje Ljungberg2, Yusuke Oji3, Haruo Sugiyama3,
Göran Roos1 and Aihong Li4
1,4Department
of Medical Biosciences,
University, Umeå, Sweden;
1
Pathology, and
2Department
4
Clinical Chemistry, Umeå
of Perioperative Sciences, Urology and
Andrology, Umeå University, Umeå, Sweden; 3Department of Functional Diagnostic
Science, Osaka University Graduate School of Medicine, Suita, Osaka, Japan
14:15 (4-6) WT1 expression as prognostic factor in endometrial cancer
Satoshi Dohi1, Satoshi Ohno1,2, Yumiko Ohno1, Satoru Kyo1, Haruo Sugiyama3
and Masaki Inoue1
1Departments
of Obstetrics and Gynecology, Kanazawa University, Graduate School of
Medical Science, Ishikawa, Japan; 2International Research and Educational Institute
for Integrated Medical Sciences, Tokyo Women’s Medical University, Tokyo, Japan;
3Department
of Functional Diagnostic Science, Osaka University Graduate School of
Medicine, Osaka, Japan
14:30 (4-7) Potential oncogenic role of WT1 in pediatric nephroblastoma
Surasak
Sangkhathat,
Samornmas
Kanngurn,
Potchanapond Graidist,
Walawee Chaiyapan, Wanwisa Maneechai
Tumor Biology Research Unit and Molecular Biology Laboratory, Faculty of Medicine,
Prince of Songkla University, Hat Yai, Songkhla, Thailand 90110
14:45 (4-8) WT1 Regulates VEGF Expression and Plays a Role in Tumor
Angiogenesis
Gregory McCarty, Ola Awad, and David Loeb
Division of Pediatric Oncology, Sidney Kimmel Comprehensive Cancer Center, Johns
Hopkins University, Baltimore, MD, USA
15:00-15:40
Coffee Break
16
The 4th International Conference on WT1 in Human Neoplasia
2009
Session III: WT1 as a disease marker and WT1 mutation/ part II
Chairs: Yuji Heike& Elizabeth M. Algar
15:40 (3-6) The significance of detecting WT1 expression in childhood
acute leukemias
Shao-Yan Hu1, Wei-ying Gu2, Zi-Xing Chen3, Xu-Li Wang1, Jian-Nong Cen3,
Hai-Long He1, Yi-Huan Chai1,
1Hematology&Oncology
Chien-Shing Chen4
Department, Children’s Hospital of Soochow University, No.
303 Jingde Road, Pingjiang district, Suzhou city, China 215003; 2Department of
Hematology, The First People’s Hospital of Changzhou, Third Affiliated to Soochow
University, Changzhou 213003, China; 3Jiangsu Institute of Hematology, First Affiliated
Hospital, Soochow University, No. 96 Shizi Street, Canglang district, Suzhou city, China.
215006; 4Cancer Institute and Division of Medical Oncology& Hematology, School of
Medicine, 11234 Anderson St. MC-1531, Loma Linda University Medical Center, Loma
Linda, CA 92354
15:55 (3-7) Standardization of Wilms’ tumor gene 1 mRNA quantitation for
minimal residual disease (MRD) monitoring in childhood AML and
implications of WT1 gene mutations: a European multicenter study
Andre M. Willasch1, Bernd Gruhn2, Tiziana Coliva3, Marketa Kalinova4, Gaby
Schneider5, Hermann Kreyenberg1, Daniel Steinbach6, Gerrit Weber1, Iris H. I.
M. Hollink7, C. Michel Zwaan7, Andrea Biondi3, Vincent H. J. van der Velden8,
Dirk Reinhardt9, Giovanni Cazzaniga3, Peter Bader1, and Jan Trka4
1Goethe
University Frankfurt, Department of Pediatric Hematology, Oncology and
Hemostaseology, Frankfurt am Main, Germany; 2Schiller University Jena, Department
of Pediatric Hematology and Oncology, Jena, Germany; 3Universitá Milano, Bicocca
Clinica Pediatrica, Ospedale San Gerardo, Monza, Italy; 4Charles University and
University Children’s Hospital, Motol, Prague, Czech Republic; 5Goethe University
Frankfurt, Department of Computer Science and Mathematics, Frankfurt am Main,
Germany; 6University Ulm, Department of Pediatric Hematology and Oncology, Ulm,
Germany; 7Erasmus MC, Sophia Children's Hospital, Rotterdam, The Netherlands;
8Erasmus
MC, Department of Immunology, Rotterdam, The Netherlands; 9AML-BFM
Study Group, Department of Pediatric Oncology and Hematology, Medical High School,
Hannover, Germany
17
The 4th International Conference on WT1 in Human Neoplasia
2009
16:10 (3-8) Rapid screening methods for germ-line and somatic WT1
mutations
Elizabeth M. Algar and Vinod Dagar
Molecular Oncology laboratory, Children’s Cancer Centre, Murdoch Children’s
Research Institute.
16:25 (3-9) Wilms Tumour 1 Mutation in Acute Myeloid Leukaemia is
associated with an adverse outcome
Jude Fitzgibbon
Centre for Medical Oncology, Institute of Cancer, Barts and the London Medical School
of Medicine and Dentistry, Turner Street, London E1 2AD, U.K.
16:40 Closing
18
The 4th International Conference on WT1 in Human Neoplasia
19
2009